Initial Experience with Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
- 1 Department of Traumatic Brain Injury Rehabilitation, Guangdong Province Work Injury Rehabilitation Hospital, Guangzhou, China
- 2 Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital, Guangzhou, China
- 3 Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital, Guangzhou, China
- 4 Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital, Guangzhou, China
- 5 Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital, Guangzhou, China
- 6 Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital, Guangzhou, China
- 7 Department of Urology, Guangdong Provincial Work Injury Rehabilitation Hospital, Guangzhou, China
Abstract
Background: Though anticholinergic drugs are considered the standard treatment for neurogenic detrusor overactivity, it is far from an ideal tool, because of their adverse effects such as Constipation or not respond sufficiently for a substantial proportion of patients. Recently mirabegron has become a commonly used overactive bladder medication in the general population, but few studies about mirabegron for the treatment of neurogenic detrusor overactivity. Objective: To evaluate the efficacy and safety of mirabegron for the treatment of neurogenic lower urinary tract dysfunction. Study Design: Prospective study. Methods: This prospective study included 13 adult patients with neurogenic lower urinary tract dysfunction as a result of spinal cord injury. All patients receiving mirabegron treatment (50 mg once daily) at least 6 weeks. The effective outcomes included the mean urine volume per catheterization, urinary incontinence episodes and Incontinence Specific Quality of Life Instrument. We monitored the blood pressure and heart rate to assess the cardiovascular safety, other adverse events were also recorded. Results: A total of 13 patients were included. After 6 weeks of treatment, all patients experienced a significant increase in the mean volume of per catheterization from 238.46 ± 65.43 ml to 327.69 ± 59.04 ml (p = 0.001). There is a significant reduction in the volume of urine leakage (463.85 ± 247.98 ml VS 180.00 ± 190.96 ml, p = 0.003) and incontinence episodes per 24 h (4.46 ± 2.03 VS 1.92 ± 1.50, p = 0.001). Significant improvement in mean Incontinence Specific Quality of Life Instrument was also found (p = 0.001). No patients reported dry mouth during the study, and the cardiovascular safety were acceptable. Conclusion: Mirabegron is safe and effective in the treatment of neurogenic lower urinary tract dysfunction. It might be a good choice for reducing the cessation of clean intermittent catheterization.
- Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., et al. (2002) The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-Committee of the International Continence Society. Neurourology and Urodynamics, 21, 167-178. https://doi.org/10.1002/nau.10052
- Schäfer, W., Abrams, P., Liao, L., Mattiasson, A., Pesce, F., Spangberg, A., et al. (2002) Good Urodynamic Practices: Uroflowmetry, Filling Cystometry, and Pressure-flow Studies. Neurourology and Urodynamics, 21, 261-274. https://doi.org/10.1002/nau.10066
- Hagen, E.M., Eide, G.E., Rekand, T., Gilhus, N.E. and Gronning, M. (2010) Traumatic Spinal Cord Injury and Concomitant Brain Injury: A Cohort Study. Acta Neurologica Scandinavica. Supplementum, 190, 51-57. https://doi.org/10.1111/j.1600-0404.2010.01376.x
- Denys, P., Corcos, J., Everaert, K., Chartier-Kastler, E., Fowler, C., Kalsi, V., et al. (2006) Improving the Global Management of the Neurogenic Bladder Patient. Part I. The Complexity of Patients. Current Medical Research and Opinion, 22, 359-365. https://doi.org/10.1185/030079906X89702
- Sugiyama, H., Uemura, O., Mori, T., et al. (2017) Effect of Imidafenacin on the Urodynamic Parameters of Patients with Indwelling Bladder Catheters Due to Spinal Cord Injury. Spinal Cord, 55, 187-191. https://doi.org/10.1038/sc.2016.168
- Kessler, T.M., Bachmann, L.M., Minder, C., Lohrer, D., Umbehr, M., Schunemann, H.J., et al. (2011) Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach. PLoS ONE, 6, e16718. https://doi.org/10.1371/journal.pone.0016718
- Yamaguchi, O. and Chapple, C.R. (2007) Beta3-Adrenoceptors in Urinary Bladder. Neurourology and Urodynamics, 26, 752-756. https://doi.org/10.1002/nau.20420
- Kumar, V., Templeman, L., Chapple, C.R. and Chess-Williams, R. (2003) Recent Developments in the Management of Detrusor Overactivity. Current Opinion in Urology, 13, 285-291. https://doi.org/10.1097/00042307-200307000-00004
- Nitti, V.W., Auerbach, S., Martin, N., Calhoun, A., Lee, M. and Herschorn, S. (2013) Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder. Journal of Urology, 189, 1388-1395. https://doi.org/10.1016/j.juro.2012.10.017
- Khullar, V., Amarenco, G., Angulo, J.C., et al. (2013) Efficacy and Tolerability of Mirabegron, a β (3)-adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial. European Urology, 63, 283-295. https://doi.org/10.1016/j.eururo.2012.10.016